HOME >> BIOLOGY >> NEWS
Final results demonstrate Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly

ORLANDO, Fla., (May 15, 2005) Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that 200 mcg of Aranesp (darbepoetin alfa) administered every two weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia. The data were presented today at the 41st Annual Meeting of the American Society of Clinical Oncology (ASCO). [Abstract #8125]

"This is the largest, randomized head-to-head comparison of darbepoetin alfa dosed every two weeks to Epoetin alfa dosed weekly, as they are most often used in current oncology practice," said John Glaspy, MD, professor, David Geffen School of Medicine, University of California at Los Angeles. "Less frequent dosing provides anemia management with less frequent injections, and for patients receiving chemotherapy every two or three weeks, less frequent office visits. Our data demonstrate that less frequent injections can be accomplished without a compromise in efficacy in terms of decreased transfusion risk or improved quality of life."

In the Phase 3 head-to-head study, a total of 1,220 patients with chemotherapy-induced anemia were randomized to receive either Aranesp 200 mcg every two weeks (n=613) or Epoetin alfa 40,000 U once a week (n=607). The majority of patients in both groups achieved the target hemoglobin of greater than or equal to 11 g/dL. Both groups of patients had similar blood transfusion rates, patient reported outcomes, and safety endpoints.

In this study, at least 90 percent of patients in both arms of the study achieved target hemoglobin of greater than or equal to 11 g/dL. Seventy-four percent of patients in the Aranesp group remained in the target range compared to 80 percent in the Epoetin alfa group. The study's primary endpoi
'"/>

Contact: Trish Hawkins
805-447-4587
Porter Novelli
16-May-2005


Page: 1 2

Related biology news :

1. Final of the 2005-06 Research Councils Business Plan Competition
2. Finally, JAP study shows headdown bedrest precisely mimics human physiology in spaceflight
3. Finally, male water fleas exposed
4. Finalists in young scholars competition announced
5. Cooperative science program yields results
6. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
7. Smelling for first time results from knowing abnormalities in congenital loss of smell
8. BDSI announces positive phase III clinical trial results
9. Scientists meet to review Envisat results after 5 years of operations
10. Environment and exercise may affect research results, UA study shows
11. Preliminary results of largest scan of autism DNA information

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/11/2018)... ... October 11, 2018 , ... ... behind the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL). The Institute, a ... to advance biopharmaceutical manufacturing and workforce development in the United States. Biopharmaceuticals are ...
(Date:10/5/2018)... YORBA LINDA, Calif. (PRWEB) , ... October 04, 2018 , ... ... inaccurate results of some of the tests such as cardiac troponin has serious clinical ... US population, although the exact prevalence is still unknown. , High dose of ...
(Date:10/2/2018)... ... October 02, 2018 , ... Stuart is a fun-loving eight-year-old Labrador retriever. Like ... his owner, Cynthia, “He loves playing ball so much that whenever anyone comes to our ... play a game of fetch.” In early 2017, Stuart began limping and eventually could ...
Breaking Biology News(10 mins):
(Date:9/28/2018)... YORBA LINDA, Calif. (PRWEB) , ... September 28, ... ... educational and interactive virtual events for tech innovators, engineers, and scientists from around ... Peru studying at the National University of San Marcos, as the winner of ...
(Date:9/27/2018)... , ... September 26, 2018 , ... ... are way ahead of their primary care physicians, according to a new Zeldis ... study, patients and doctors were asked about consumer adoption of fitness and health ...
(Date:9/27/2018)... ... 26, 2018 , ... Nvision Biomedical Technologies , a ... today at the North American Spine Society (NASS) Annual Meeting, held at the ... Screw System, which received clearance from the U.S. Food and Drug Administration (FDA) ...
(Date:9/27/2018)... Hungary and CAMBRIDGE, Mass. (PRWEB) , ... September ... ... in Budapest with US offices in Cambridge, MA, announce today that Holotype HLA ... or collaborators at the annual meeting of the American Society for Histocompatibility and ...
Breaking Biology Technology:
Cached News: